Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17002016 | 0.92 | KDM4E (0.33) | KDM4EMEN1ALDH1A1LMNACYP1A2 | |
| SCHEMBL16743442 | 0.87 | — | — | |
| SCHEMBL859539 | 0.79 | — | — | |
| SCHEMBL16743443 | 0.79 | ALDH1A1 (0.33) | KDM4EMEN1ALDH1A1LMNACYP1A2 | |
| SCHEMBL858589 | 0.75 | MEN1 (0.39) | KDM4EMEN1ALDH1A1LMNACYP1A2 | |
| SCHEMBL13066825 | 0.72 | ALDH1A1 (0.49) | KDM4EMEN1ALDH1A1LMNACYP1A2 | |
| SCHEMBL859706 | 0.72 | ALDH1A1 (0.43) | KDM4EMEN1ALDH1A1LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL859818 | 0.71 | ALDH1A1 (0.43) | KDM4EMEN1ALDH1A1LMNACYP1A2 | |
| SCHEMBL16998643 | 0.65 | — | — | |
| SCHEMBL16998642 | 0.64 | HPGD (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | KDM4E 3841/4885MEN1 4378/4885ALDH1A1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.